US02155H2004
US02155H2004
Altimmune, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 507.69M EUR | 591.2M EUR | 401.08M EUR | 400.29M EUR |
Enterprise Value | 217.43M EUR | 564.21M EUR | 339.33M EUR | 392.21M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -3.91x | -- | -- | -- |
Price to Sales | 16,377.14x | 19,071.01x | 11,141.14x | 11,119.07x |
Price to Book | 1.07x | 1.25x | 1.41x | 1.78x |
EV/Revenue | 7,013.88x | 18,200.43x | 9,425.75x | 10,894.85x |
EV/EBITDA | -2.2x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -9.61% | -12.95% | -17.87% | -12.67% |